Board Change • Dec 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. お知らせ • Oct 20
Zoono Group Limited, Annual General Meeting, Nov 20, 2025 Zoono Group Limited, Annual General Meeting, Nov 20, 2025. Location: hall chadwick, level 40, 2 park street, sydney nsw 2000 Australia お知らせ • Aug 28
Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 1.777229 million. Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 1.777229 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,428,730
Price\Range: AUD 0.035
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 28,349,219
Price\Range: AUD 0.035
Transaction Features: Rights Offering お知らせ • Jun 21
Zoono Group Limited has filed a Follow-on Equity Offering in the amount of AUD 1.777169 million. Zoono Group Limited has filed a Follow-on Equity Offering in the amount of AUD 1.777169 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,776,259
Price\Range: AUD 0.035
Transaction Features: Rights Offering Board Change • Dec 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. お知らせ • Oct 11
Zoono Group Limited, Annual General Meeting, Nov 13, 2024 Zoono Group Limited, Annual General Meeting, Nov 13, 2024. Location: hall chadwick, level 40, 2 park street, sydney nsw 2000, Australia Reported Earnings • Aug 22
Full year 2024 earnings released: NZ$0.041 loss per share (vs NZ$0.002 loss in FY 2023) Full year 2024 results: NZ$0.041 loss per share (further deteriorated from NZ$0.002 loss in FY 2023). Revenue: NZ$1.05m (down 69% from FY 2023). Net loss: NZ$9.09m (loss widened NZ$8.74m from FY 2023). New Risk • May 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 99% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 32% per year over the past 5 years. Shareholders have been substantially diluted in the past year (99% increase in shares outstanding). Market cap is less than US$10m (AU$9.69m market cap, or US$6.46m). Minor Risk Revenue is less than US$5m (NZ$2.1m revenue, or US$1.3m). お知らせ • May 18
Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.366507 million. Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.366507 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,574,320
Price\Range: AUD 0.027
Transaction Features: Subsequent Direct Listing Reported Earnings • Feb 25
First half 2024 earnings released: NZ$0.031 loss per share (vs NZ$0.008 profit in 1H 2023) First half 2024 results: NZ$0.031 loss per share (down from NZ$0.008 profit in 1H 2023). Revenue: NZ$650.4k (down 65% from 1H 2023). Net loss: NZ$5.93m (down NZ$7.30m from profit in 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. お知らせ • Feb 14
Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.054 million. Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.054 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.027
Transaction Features: Subsequent Direct Listing Board Change • Jan 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. お知らせ • Oct 06
Zoono Group Limited, Annual General Meeting, Nov 27, 2023 Zoono Group Limited, Annual General Meeting, Nov 27, 2023, at 11:01 AUS Eastern Standard Time. Board Change • Oct 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
Full year 2023 earnings released: NZ$0.002 loss per share (vs NZ$0.069 loss in FY 2022) Full year 2023 results: NZ$0.002 loss per share (improved from NZ$0.069 loss in FY 2022). Revenue: NZ$3.34m (down 63% from FY 2022). Net loss: NZ$350.4k (loss narrowed 97% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. New Risk • Aug 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 8.4% per year over the past 5 years. Market cap is less than US$10m (AU$8.55m market cap, or US$5.49m). Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (NZ$4.8m revenue, or US$2.8m). Reported Earnings • Feb 24
First half 2023 earnings released: EPS: NZ$0.008 (vs NZ$0.012 loss in 1H 2022) First half 2023 results: EPS: NZ$0.008 (up from NZ$0.012 loss in 1H 2022). Revenue: NZ$1.85m (down 70% from 1H 2022). Net income: NZ$1.37m (up NZ$3.36m from 1H 2022). Profit margin: 74% (up from net loss in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 20 percentage points per year, which is a significant difference in performance. Board Change • Nov 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
Full year 2022 earnings released: NZ$6.82 loss per share (vs NZ$0.029 profit in FY 2021) Full year 2022 results: NZ$6.82 loss per share (down from NZ$0.029 profit in FY 2021). Revenue: NZ$9.02m (down 67% from FY 2021). Net loss: NZ$11.4m (down 341% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 208 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Jan 25
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be NZ$0.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 92% per annum over the last 3 years. Earnings per share has grown by 91% per annum over the last 3 years. Reported Earnings • Aug 28
Full year 2021 earnings released: EPS NZ$0.029 (vs NZ$0.10 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: NZ$27.1m (down 29% from FY 2020). Net income: NZ$4.73m (down 72% from FY 2020). Profit margin: 17% (down from 44% in FY 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 91% per year whereas the company’s share price has increased by 88% per year. Recent Insider Transactions • Jun 11
CEO, MD & Director recently sold AU$4.9m worth of stock On the 3rd of June, Paul Hyslop sold around 7m shares on-market at roughly AU$0.70 per share. This was the largest sale by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improved over the past week After last week's 20% share price gain to NZ$1.04, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 32x in the Chemicals industry in Australia. Total returns to shareholders of 604% over the past three years. Reported Earnings • Mar 02
First half 2021 earnings released: EPS NZ$0.012 (vs NZ$0.004 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: NZ$14.4m (up NZ$12.7m from 1H 2020). Net income: NZ$1.91m (up NZ$2.63m from 1H 2020). Profit margin: 13% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 11
New 90-day low: AU$0.93 The company is down 34% from its price of AU$1.42 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NZ$1.05, the stock is trading at a trailing P/E ratio of 10.9x, down from the previous P/E ratio of 13.1x. This compares to an average P/E of 36x in the Chemicals industry in Australia. Total returns to shareholders over the past three years are 268%. Is New 90 Day High Low • Jan 18
New 90-day low: AU$1.27 The company is down 17% from its price of AU$1.53 on 21 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is flat over the same period. Is New 90 Day High Low • Dec 12
New 90-day low: AU$1.32 The company is down 39% from its price of AU$2.15 on 11 September 2020. The Australian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 24
New 90-day low: AU$1.33 The company is down 43% from its price of AU$2.33 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 2.0% over the same period. Valuation Update With 7 Day Price Move • Nov 03
Market bids up stock over the past week After last week's 21% share price gain to NZ$1.61, the stock is trading at a trailing P/E ratio of 16.5x, up from the previous P/E ratio of 13.7x. This compares to an average P/E of 18x in the Chemicals industry in Australia. Total returns to shareholders over the past three years are 283%. Is New 90 Day High Low • Oct 28
New 90-day low: AU$1.33 The company is down 41% from its price of AU$2.27 on 30 July 2020. The Australian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period. Valuation Update With 7 Day Price Move • Oct 16
Market pulls back on stock over the past week After last week's 15% share price decline to NZ$1.55, the stock is trading at a trailing P/E ratio of 15.1x, down from the previous P/E ratio of 17.9x. This compares to an average P/E of 19x in the Chemicals industry in Australia. Total returns to shareholders over the past three years are 231%. Is New 90 Day High Low • Sep 30
New 90-day low: AU$1.80 The company is down 42% from its price of AU$3.10 on 02 July 2020. The Australian market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is flat over the same period.